Events And

NASH-TAG Conference

Jan 04 - Jan 06, 2024

Presentation: Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (abstract #51)

Authors: Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. Browne

Supporting Materials


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail